StockNews.com upgraded shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a sell rating to a hold rating in a research note published on Saturday.
A number of other research firms have also recently weighed in on ABUS. JMP Securities increased their price target on Arbutus Biopharma from $4.00 to $5.00 and gave the stock a market outperform rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a buy rating and set a $5.00 target price on shares of Arbutus Biopharma in a research note on Thursday, June 6th. Finally, Chardan Capital reissued a buy rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Wednesday, June 5th.
Get Our Latest Report on Arbutus Biopharma
Arbutus Biopharma Price Performance
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The firm had revenue of $1.73 million for the quarter, compared to analysts’ expectations of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. During the same period in the previous year, the firm posted ($0.10) EPS. Sell-side analysts forecast that Arbutus Biopharma will post -0.38 EPS for the current year.
Institutional Investors Weigh In On Arbutus Biopharma
Hedge funds have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC acquired a new position in shares of Arbutus Biopharma during the first quarter worth about $266,000. BNP Paribas Financial Markets boosted its stake in Arbutus Biopharma by 19.7% in the first quarter. BNP Paribas Financial Markets now owns 349,435 shares of the biopharmaceutical company’s stock valued at $902,000 after acquiring an additional 57,390 shares in the last quarter. Kennedy Capital Management LLC grew its holdings in shares of Arbutus Biopharma by 12.7% during the first quarter. Kennedy Capital Management LLC now owns 436,506 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 49,265 shares during the last quarter. Walleye Trading LLC acquired a new stake in shares of Arbutus Biopharma during the first quarter worth about $36,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Arbutus Biopharma by 15.3% in the 4th quarter. SG Americas Securities LLC now owns 46,172 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 6,117 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Articles
- Five stocks we like better than Arbutus Biopharma
- How to Read Stock Charts for Beginners
- How to Invest in Silver: A Beginner’s Guide
- Best Stocks Under $10.00
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Using the MarketBeat Dividend Yield Calculator
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.